None
SEDAR Interim Financial Statements
METX · Price
[
{
"companyName": "ME Therapeutics Holdings Inc.",
"reportingPeriodEnd": "2025-11-30",
"reportStatus": "Unaudited",
"auditorName": null,
"auditorKeyMatters": [],
"balanceSheet": {
"cash": 1188353,
"shortTermInvestment": 57500,
"salesTaxReceivable": 52736,
"governmentAssistanceReceivable": 11,
"prepaidExpenses": 22319,
"totalCurrentAssets": 1320908,
"securityDeposit": 10891,
"propertyAndEquipment": 221528,
"intangibleAsset": 1,
"totalNonCurrentAssets": 232420,
"totalAssets": 1553328,
"accountsPayableAndAccruedLiabilities": 131769,
"dueToRelatedParties": 31500,
"leaseLiabilityCurrent": 57391,
"totalCurrentLiabilities": 220660,
"leaseLiabilityNonCurrent": 0,
"totalLiabilities": 220660,
"shareCapital": 8918870,
"reserves": 2433898,
"deficit": -10020100,
"totalShareholdersEquity": 1332668,
"totalLiabilitiesAndShareholdersEquity": 1553328,
"cashPerShare": 0.0399,
"workingCapitalPerShare": 0.0369
},
"incomeStatement": {
"consulting": 78000,
"depreciation": 26516,
"financeCharges": 2308,
"generalAndAdministrative": 79020,
"professionalFees": 56535,
"researchCosts": 141838,
"shareBasedCompensation": 0,
"lossFromOperatingExpenses": -384217,
"interestIncome": 6097,
"governmentAssistance": 23687,
"lossAndComprehensiveLossForThePeriod": -354433,
"weightedAverageNumberOfCommonSharesOutstandingBasic": 29791692,
"weightedAverageNumberOfCommonSharesOutstandingDiluted": 29791692,
"basicLossPerShare": -0.01,
"dilutedLossPerShare": -0.01
},
"cashFlowStatement": {
"lossForThePeriod": -354433,
"depreciation": 26516,
"financeCharges": 2308,
"shareBasedCompensation": 0,
"salesTaxReceivable": -8738,
"governmentAssistanceReceivable": 24193,
"prepaidExpenses": 8699,
"accountsPayableAndAccruedLiabilities": -23439,
"dueToRelatedParties": 2100,
"netCashUsedInOperatingActivities": -322794,
"proceedsFromExerciseOfWarrants": 184000,
"paymentOfLeaseLiabilities": -16577,
"netCashFromFinancingActivities": 167423,
"paymentOfSecurityDeposit": 0,
"purchaseOfEquipment": -1653,
"netCashUsedInInvestingActivities": -1653,
"netChangeInCash": -157024,
"cashBeginningOfPeriod": 1345377,
"cashEndOfPeriod": 1188353
},
"investmentsAndOtherAssets": [
{
"type": "Marketable Securities",
"description": "Short-term investment",
"ownershipPercentage": null,
"value": 57500,
"notes": null
},
{
"type": "Other",
"description": "Security deposit for lease",
"ownershipPercentage": null,
"value": 10891,
"notes": "Refundable security deposit for lab and office space lease."
},
{
"type": "Intangible Asset",
"description": "Novel antibody sequences",
"ownershipPercentage": null,
"value": 1,
"notes": "Capitalized intangible asset costs."
}
],
"shareStructure": {
"authorizedShares": "unlimited",
"issuedShares": 30049494,
"classesOfShares": ["common", "preferred"],
"warrants": [
{
"number": 347220,
"exercisePrice": 1.0,
"expiryDate": "2026-03-01"
},
{
"number": 1555000,
"exercisePrice": 1.5,
"expiryDate": "2026-03-06"
},
{
"number": 1250000,
"exercisePrice": 0.2,
"expiryDate": "2027-01-13"
},
{
"number": 800000,
"exercisePrice": 0.25,
"expiryDate": "2027-01-26"
},
{
"number": 500000,
"exercisePrice": 0.4,
"expiryDate": "2027-10-21"
}
],
"options": [
{
"number": 2175000,
"exercisePrice": 0.45,
"expiryDate": "2026-03-31"
},
{
"number": 250000,
"exercisePrice": 0.45,
"expiryDate": "2026-06-07"
},
{
"number": 250000,
"exercisePrice": 3.51,
"expiryDate": "2027-04-08"
},
{
"number": 121670,
"exercisePrice": 0.4,
"expiryDate": "2028-03-09"
}
],
"rightsConvertibleInstruments": null
},
"managementCompensation": {
"currency": "CAD",
"periods": {
"2025": {
"consulting": 51000,
"professionalFees": 18000,
"shareBasedCompensation": 0
},
"2024": {
"consulting": 37000,
"professionalFees": 12000,
"shareBasedCompensation": 637291
}
},
"namedIndividuals": [
{
"name": "CEO",
"title": "Chief Executive Officer",
"period": "2025",
"components": {
"salary": null,
"bonus": null,
"total": 30000
}
},
{
"name": "CEO",
"title": "Chief Executive Officer",
"period": "2024",
"components": {
"salary": null,
"bonus": null,
"total": 30000
}
},
{
"name": "Former CBO",
"title": "Former Chief Business Officer",
"period": "2025",
"components": {
"salary": null,
"bonus": null,
"total": 21000
}
},
{
"name": "Former CBO",
"title": "Former Chief Business Officer",
"period": "2024",
"components": {
"salary": null,
"bonus": null,
"total": 7000
}
},
{
"name": "CFO",
"title": "Chief Financial Officer",
"period": "2025",
"components": {
"salary": null,
"bonus": null,
"total": 18000
}
},
{
"name": "CFO",
"title": "Chief Financial Officer",
"period": "2024",
"components": {
"salary": null,
"bonus": null,
"total": 12000
}
}
],
"otherRelatedPartyTransactions": []
},
"subsequentEvents": []
}
]
More from ME Therapeutics Holdings Inc
Jun 03, 2026 · 15:13